Monday, 31 August 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

NORDIC NANOVECTOR Stock Rises By 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) rose by a staggering 33.1% in 21 sessions from kr1.45 to kr1.93 at 05:39 EST on Tuesday, after five sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is jumping 0.23% to kr1,201.66, after two sequential sessions in a row of gains.

NORDIC NANOVECTOR's last close was kr1.62, 51.47% under its 52-week high of kr3.34.

About NORDIC NANOVECTOR

Thor Medical AS produces alpha-emitters for radiopharmaceuticals to treat cancer. The company was incorporated in 2017 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-2.41.

Yearly Top and Bottom Value

NORDIC NANOVECTOR's stock is valued at kr1.93 at 05:39 EST, way below its 52-week high of kr3.34 and way above its 52-week low of kr0.65.

More news about NORDIC NANOVECTOR (NANOV.OL).

Categories

stockMarket

Tags

Stock PriceMarket Session NowStock Market NowPrice UpMarket SessionStock Price UpNANOV.OLNORDIC NANOVECTORStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com